Last reviewed · How we verify
Influenza antigen
At a glance
| Generic name | Influenza antigen |
|---|---|
| Sponsor | Eurocine Vaccines AB |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RSV Burden in Outpatient and Hospital Settings (NA)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (PHASE1)
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus (PHASE1, PHASE2)
- CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 (PHASE1)
- Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza antigen CI brief — competitive landscape report
- Influenza antigen updates RSS · CI watch RSS
- Eurocine Vaccines AB portfolio CI